of compliance with 39 U.S.C. 3633(a), and an application for non-public treatment of certain materials. It also filed supporting financial workpapers.

II. Notice of Commission Action


The Commission appoints Curtis E. Kidd to serve as Public Representative in this docket.

III. Ordering Paragraphs

It is ordered:


2. Pursuant to 39 U.S.C. 505, Curtis E. Kidd is appointed to serve as an officer of the Commission to represent the interests of the general public in this proceeding (Public Representative).

3. Comments are due no later than April 22, 2015.

4. The Secretary shall arrange for publication of this order in the Federal Register.

By the Commission.

Shoshana M. Grove, Secretary.

B. Requests for Oral Comments

Interested persons may present comments at the public meeting. Comments will be scheduled to begin approximate at 11:40 a.m. Time allotted for comments may be limited to 3 minutes, dependent on number of requests received. Those desiring to make oral comments should notify Jane Reese-Coulbourne or make oral comments should notify Jane Reese-Coulbourne (see FOR FURTHER INFORMATION CONTACT) by May 8, 2015. Please include a brief statement of the general nature of the comments they wish to present along with your name, address, telephone number, and email.

The agenda for the public meeting will be posted on the event registration page: http://goo.gl/6X6ysw and the Reagan-Udall Web site: http://goo.gl/ASVymH.

C. Written Comments

Interested persons may submit either electronic or written comments to the Foundation at any time to Comments@ReaganUdall.org or by mail to the Reagan-Udall Foundation for the FDA, 1025 Connecticut Ave. NW., Suite 1000, Washington, DC 20036. Please include your name, address, telephone number, and email when making comments.

III. Post-Meeting Materials

The Foundation plans to make meeting materials and meeting recording available to the public after the meeting. Once available, these materials will be posted at http://goo.gl/ASVymH.

Dated: April 15, 2015.

Jane Reese-Coulbourne, Executive Director, Reagan-Udall Foundation for the FDA.